BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 8317901)

  • 1. Serum soluble interleukin-2 receptor (sIL-2R) assay in cervical and endometrial cancer. Preliminary data.
    Ferdeghini M; Gadducci A; Prontera C; Marrai R; Malagnino G; Annicchiarico C; Fioretti P; Bianchi R
    Anticancer Res; 1993; 13(3):709-13. PubMed ID: 8317901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer.
    Gadducci A; Ferdeghini M; Malagnino G; Prontera C; Fanucchi A; Annicchiarico C; Bianchi R; Fioretti P; Facchini V
    Gynecol Oncol; 1994 Mar; 52(3):386-91. PubMed ID: 8157196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of clinical staging in cervical cancer with serum squamous cell carcinoma antigen and CA 125 determinations.
    Massuger LF; Koper NP; Thomas CM; Dom KE; Schijf CP
    Gynecol Oncol; 1997 Mar; 64(3):473-6. PubMed ID: 9062153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative serum squamous cell carcinoma antigen levels in clinical decision making for patients with early-stage cervical cancer.
    Reesink-Peters N; van der Velden J; Ten Hoor KA; Boezen HM; de Vries EG; Schilthuis MS; Mourits MJ; Nijman HW; Aalders JG; Hollema H; Pras E; Duk JM; van der Zee AG
    J Clin Oncol; 2005 Mar; 23(7):1455-62. PubMed ID: 15735121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum CYFRA 21-1 assay in squamous cell carcinoma of the cervix.
    Ferdeghini M; Gadducci A; Annicchiarico C; Prontera C; Malagnino G; Castellani C; Facchini V; Bianchi R
    Anticancer Res; 1993; 13(5C):1841-4. PubMed ID: 7505543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of RCAS1 as a biomarker of uterine cancer.
    Sonoda K; Miyamoto S; Hirakawa T; Yagi H; Yotsumoto F; Nakashima M; Watanabe T; Nakano H
    Gynecol Oncol; 2006 Dec; 103(3):924-31. PubMed ID: 16842844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between serum levels of soluble interleukin-2 receptor and various disease parameters in patients with squamous cell carcinoma of the esophagus.
    Oka M; Hazama S; Takahashi M; Yamamoto K; Abe T; Yoshino S; Hayashi H; Tangoku A
    Hepatogastroenterology; 1999; 46(28):2254-9. PubMed ID: 10521976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [SCC (squamous cell carcinoma) antigen as a tumor marker in cervix cancers].
    Geyer H; Schwörer D; Pfleiderer A
    Geburtshilfe Frauenheilkd; 1989 Mar; 49(3):266-71. PubMed ID: 2721888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?
    Gaarenstroom KN; Kenter GG; Bonfrer JM; Korse CM; Van de Vijver MJ; Fleuren GJ; Trimbos JB
    Gynecol Oncol; 2000 Apr; 77(1):164-70. PubMed ID: 10739706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
    Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
    Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor markers CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen in patients with adenocarcinoma of the uterine cervix.
    Duk JM; Aalders JG; Fleuren GJ; Krans M; De Bruijn HW
    Obstet Gynecol; 1989 Apr; 73(4):661-8. PubMed ID: 2648225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Experiences with the squamous cell carcinoma antigen, a new tumor marker for cancer of the uterine cervix].
    Meier W; Eiermann W; Stieber P; Fateh-Moghadam A; Hepp H
    Geburtshilfe Frauenheilkd; 1989 Jul; 49(7):625-9. PubMed ID: 2777050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early predicting recurrent cervical cancer with combination of tissue polypeptide specific antigen (TPS) and squamous cell carcinoma antigen (SCC).
    Hung YC; Shiau YC; Chang WC; Kao CH; Lin CC
    Neoplasma; 2002; 49(6):415-7. PubMed ID: 12584591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of squamous cell carcinoma antigen and ovarian carcinoma antigen (CA 125) in patients with benign and malignant diseases of the uterine cervix.
    Gocze PM; Vahrson HW; Freeman DA
    Oncology; 1994; 51(5):430-4. PubMed ID: 8052484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SCC-Ag, lymph node metastases and sentinel node procedure in early stage squamous cell cervical cancer.
    van de Lande J; Davelaar EM; von Mensdorff-Pouilly S; Water TJ; Berkhof J; van Baal WM; Kenemans P; Verheijen RH
    Gynecol Oncol; 2009 Jan; 112(1):119-25. PubMed ID: 19007978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
    Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
    Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of pretreatment squamous cell carcinoma antigen and carcinoembryonic antigen in squamous cell carcinoma of the uterine cervix.
    Bae SN; Namkoong SE; Jung JK; Kim CJ; Park JS; Kim JW; Lee JM; Kim SJ
    Gynecol Oncol; 1997 Mar; 64(3):418-24. PubMed ID: 9062143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of various epithelial tumor markers and a stromal marker in the assessment of cervical carcinoma.
    Tomás C; Risteli J; Risteli L; Vuori J; Kauppila A
    Obstet Gynecol; 1991 Apr; 77(4):566-72. PubMed ID: 2002979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of pre-treatment CYFRA 21 - 1 and SCC-Antigen assay in primary cervical carcinoma - a preliminary report.
    Puthucode-Easwaran S; Naik R; Athavale R; Handley G; Lopes A; Godfrey K; Hatem M
    J Obstet Gynaecol; 2005 Jul; 25(5):486-8. PubMed ID: 16183586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune activation in cervical neoplasia: cross-sectional association between plasma soluble interleukin 2 receptor levels and disease.
    Hildesheim A; Schiffman MH; Tsukui T; Swanson CA; Lucci J; Scott DR; Glass AG; Rush BB; Lorincz AT; Corrigan A; Burk RD; Helgesen K; Houghten RA; Sherman ME; Kurman RJ; Berzofsky JA; Kramer TR
    Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):807-13. PubMed ID: 9332763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.